Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.2K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.2K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Cancer Survival Analysis01:21

Cancer Survival Analysis

862
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
862
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing the quality and trustworthiness of large language model-generated summaries of clinical oncology literature.

JAMIA open·2026
Same author

Genetic ancestry-concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer.

Cancer·2026
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

JCO precision oncology·2026
Same author

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory Properties.

Research square·2026
Same author

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Future oncology (London, England)·2026
Same journal

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

A Virtual Reality Psychosocial Intervention for Patients Undergoing Bone Marrow Transplantation (BMT-VR): Pilot Randomized Clinical Trial.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Nationwide Trends in Colorectal Cancer Screening by the End of the COVID-19 Pandemic: Racial/Ethnic Differences and Opportunities.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Evaluation of the Impact of Adjuvant Immunotherapy in Merkel Cell Carcinoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Payers' Views on Insurance Coverage for Confirmatory Diagnostics After a Noncovered Multicancer Early Detection (MCED) Test.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same journal

Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Prostate cancer, version 2.2014.

James L Mohler, Philip W Kantoff, Andrew J Armstrong

    Journal of the National Comprehensive Cancer Network : JNCCN
    |May 10, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Prostate cancer is now the most common cancer in US men. These NCCN guidelines offer updated recommendations for localized prostate cancer management, including active surveillance and imaging principles.

    More Related Videos

    miRNA Expression Analyses in Prostate Cancer Clinical Tissues
    11:29

    miRNA Expression Analyses in Prostate Cancer Clinical Tissues

    Published on: September 8, 2015

    10.3K
    Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
    07:01

    Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

    Published on: August 29, 2016

    14.1K

    Related Experiment Videos

    Last Updated: Apr 30, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    13.4K
    miRNA Expression Analyses in Prostate Cancer Clinical Tissues
    11:29

    miRNA Expression Analyses in Prostate Cancer Clinical Tissues

    Published on: September 8, 2015

    10.3K
    Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
    07:01

    Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

    Published on: August 29, 2016

    14.1K

    Area of Science:

    • Oncology
    • Urology

    Background:

    • Prostate cancer is the most common cancer in US men, surpassing lung cancer.
    • Clinical management guidelines are essential for optimal patient outcomes.

    Purpose of the Study:

    • To present updated NCCN Guidelines for Prostate Cancer management.
    • Focus on multidisciplinary recommendations for localized disease based on evidence and expert consensus.

    Main Methods:

    • Review of clinical evidence and expert consensus by the NCCN Panel.
    • Inclusion of updated guidance on treatment decisions for localized prostate cancer.

    Main Results:

    • Significant updates for early prostate cancer include distinguishing active surveillance from observation.
    • New section on principles of prostate cancer imaging introduced.
    • Revisions to radiation therapy recommendations for localized disease provided.

    Conclusions:

    • The updated NCCN Guidelines offer critical advancements in managing localized prostate cancer.
    • These guidelines emphasize distinctions in surveillance strategies and incorporate new imaging principles and radiation recommendations.